We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech’s CLL Drug Could Get FDA Decision By Year’s End
Genentech’s CLL Drug Could Get FDA Decision By Year’s End
July 3, 2013
Genentech has received more good news from the FDA regarding its blood cancer drug obinutuzumab — this time in the form of a priority review designation.